Key Updates in Non–Small Cell Lung Cancer Emerging From WCLC 2025 - Episode 2

How Cemiplimab Plus Chemo Has Affected First-Line NSCLC Management, Including Squamous Histology

,

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

EP. 1: Treatment Decision-Making and Sequencing Factors in Advanced Non–Small Cell Lung Cancer
Now Viewing
EP. 2: How Cemiplimab Plus Chemo Has Affected First-Line NSCLC Management, Including Squamous Histology
EP. 3: Managing Immune-Related AEs in NSCLC
EP. 4: 5-Year EMPOWER-Lung 3 Data for Cemiplimab Plus Chemo in Advanced NSCLC
EP. 5: Navigating Immunotherapy in Advanced NSCLC After Early-Stage IO Therapy
EP. 6: Eye-Catching Data From the 2025 World Conference on Lung Cancer
EP. 7: Future Avenues of Research in Advanced NSCLC

Related Content:

UC San Diego Health Moores Cancer CenterThe University of Texas MD Anderson Cancer CenterKey Updates in Non–Small Cell Lung Cancer Emerging From WCLC 2025OncLive News Network®Lung Cancer
Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis
Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL
Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML